Biofilms can cause significant problems in medical settings (e.g. persistent and recurrent infections, device-related infections). The Calgary Biofilm Device (CBD) has been described as a technology for the rapid and reproducible assay of biofilm susceptibilities to antibiotics. In this study a simple and inexpensive alternative to the CBD was developed from polypropylene (PP) microcentrifuge tubes and pipette tip boxes. The utility of the device was demonstrated quantitatively using Candida glabrata clinical strain, a yeast that can develop antimicrobial-resistant biofilm communities. The method was found to produce uniform and reproducible results with no significant differences between biofilms formed on PP tubes incubated in various compartments of the device. In addition, the difference between maximum and minimum counts were comparable to those which have been reported for the CBD. Qualitative data, which were obtained using scanning electron microscopy, demonstrated the high density of cells rather than production of large amounts of the external matrix are responsible on biomass production in C. glabrata biofilm.